Sugi Predict

Sugi Predict / Compounds / SCHEMBL972717

SCHEMBL972717

SCHEMBL972717

O=[N+]([O-])c1ccc(OP(=O)(Cl)Oc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.67
▸ CA2 P00918 3/20 0.67
▸ CES2 O00748 1/20 0.67
▸ CES1 P23141 1/20 0.67
▸ ACHE P22303 2/20 0.57
▸ BCHE P06276 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ MAPK1 P28482 3/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ TP53 P04637 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ TSHR P16473 1/20 0.51
▸ HSPB1 P04792 1/20 0.48
▸ CA9 Q16790 1/20 0.47
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18089635 0.93 CA1 (0.59) CA1CA2CES2CES1ACHE
SCHEMBL8427162 0.89 ALDH1A1 (0.63) CA1CA2CES2CES1ACHE
SCHEMBL851431 0.88 CA1 (0.67) CA1CA2CES2CES1ACHE
SCHEMBL18730273 0.86 CA1 (0.65) CA1CA2CES2CES1ACHE
SCHEMBL972719 0.85 CA1 (0.73) CA1CA2CES2CES1ACHE
SCHEMBL9316829 0.85 CES2 (0.68) CA1CA2CES2CES1ACHE
SCHEMBL6049724 0.85 CA1 (0.62) CA1CA2CES2CES1ACHE
SCHEMBL35319 0.83 CA1 (0.71) CA1CA2CES2CES1ACHE
SCHEMBL8877085 0.82 ALDH1A1 (0.64) CA1CA2CES2CES1ACHE
SCHEMBL1097455 0.82 ALDH1A1 (0.64) CA1CA2CES2CES1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221459-B2 Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides MEDIVIR AB (SE) 2025-02-11 — — US disclosed
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-11-30 — — US disclosed
CN-110804072-B Dioxolane analogues of uridine for use in the treatment of cancer 美迪维尔公司 2023-05-12 — — CN disclosed
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 — — US disclosed
US-11530298-B2 Poly(phosphoesters) for delivery of nucleic acids TRANSLATE BIO, INC. (US) 2022-12-20 — — US disclosed
CN-115087659-A Antiviral compounds 吉利德科学公司 2022-09-20 — — CN disclosed
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer MEDIVIR AB (SE) 2022-09-20 — — US disclosed
EP-3572410-B1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2022-07-20 — — EP disclosed
EP-3638716-B1 POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS TRANSLATE BIO INC (US) 2022-01-05 — — EP disclosed
CN-108676047-B HCV polymerase inhibitors 美迪维尔公司 2021-04-02 — — CN disclosed
EP-1165570-B1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS INC (US) 2006-08-23 — — EP disclosed
EP-1634886-A2 Novel phosphorus-containing prodrug Metabasis Therapeutics, Inc. (US) 2006-03-15 — — EP disclosed
EP-1165570-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS Metabasis Therapeutics, Inc. (US) 2002-01-02 — — EP disclosed
WO-2000052015-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2000-09-08 — — WO disclosed
EP-0537947-A1 Naphthoquinone derivatives for the treatment of parasitic infections THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-21 — — EP disclosed
WO-1993007156-A1 NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF PARASITIC INFECTIONS THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-15 — — WO disclosed
EP-0272330-B1 1,1,2-TRIARYL-1-BUTENE DERIVATIVES TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1991-05-22 — — EP disclosed
US-4897503-A ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY TAIHO PHARMACEUTICAL (JP) 1990-01-30 — — US disclosed
EP-0272330-A1 1,1,2-TRIARYL-1-BUTENE DERIVATIVES TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1988-06-29 — — EP disclosed
US-4145540-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530298-B2 Poly(phosphoesters) for delivery of nucleic acids POLR2E, POLR2H, POLR1A CA1 3179/4885CA2 4134/4885CES2 1274/4885
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NT5C CA1 4735/4885CA2 4865/4885CES2 2443/4885
US-12221459-B2 Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides PNP, NUDT1, TYMP CA1 4111/4885CA2 2702/4885CES2 3515/4885
US-11447511-B2 Dioxolane analogues of uridine for the treatment of cancer ADORA3, DUT, NTPCR CA1 4799/4885CA2 4866/4885CES2 2330/4885
US-20230382931-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR CA1 4799/4885CA2 4866/4885CES2 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.